Diphenyl diselenide alleviates diabetic peripheral neuropathy in rats with streptozotocin-induced diabetes by modulating oxidative stress.

This study aimed to evaluate its preventive and therapeutic effects on DPN in rats with streptozotocin (STZ)-induced diabetes and explore the underlying mechanisms. In vitro, RSC96 cells were exposed to high glucose (100 mM) and then treated with different concentrations of DPDs (1, 10, 25 and 50 μM). Notably, DPDs markedly suppressed high glucose-induced cytotoxicity and oxidative stress in Schwann cells by decreasing reactive oxygen species (ROS) and malondialdehyde (MDA) levels. Furthermore, the DPDs treatment effectively activated Nrf2 signaling and inhibited Keap1 expression. An in vivo DPN model was established in Sprague-Dawley (SD) rats injected with STZ (60 mg· kg-1, ip) and orally administered either different doses of DPDs (5 and 15 mg· kg-1· d-1) for 12 weeks or alpha lipoic acid (ALA, 100 mg· kg-1· d-1) as a positive control. The administration of DPDs significantly increased the motor nerve conduction velocity (MNCV), improved thermal and mechanical hyperalgesia and the sciatic nerve morphology, and ameliorated oxidative stress in the serum and the sciatic nerve of rats with DPN. Mechanistically, DPDs reduced the level of Keap1 and stimulated Nrf2 signaling in the sciatic nerve. Taken together, the results of this study indicate that DPDs ameliorates experimental DPN as an antioxidant by activating the Nrf2/Keap1 signaling pathway. DPDs may represent a new alternative treatment for DPN. PMID: 32949583 [PubMed - as suppl...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research

Related Links:

HbA1c variability has been linked to retinopathy, renal disease and autonomic neuropathy in patients with type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D). Although the same relationship has b...
Source: Diabetology and Metabolic Syndrome - Category: Endocrinology Authors: Tags: Short report Source Type: research
CONCLUSIONS: We are very uncertain whether ALC causes a reduction in pain after 6 to 12 months' treatment in people with DPN, when compared with placebo, as the evidence is sparse and of low certainty. Data on functional and sensory impairment and symptoms are lacking, or of very low certainty. The evidence on adverse events is too uncertain to make any judgements on safety. PMID: 31201734 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
This study aimed to compare the effect of high-intensity interval training (HIIT) with moderate-intensity continuous training (MCT) on endothelial function, oxidative stress and clinical fitness in patients with type 1 diabetes. Thirty-six type 1 diabetic patients (mean age 23.5 ± 6 years) were randomized into 3 groups: HIIT, MCT, and a non-exercising group (CON). Exercise was performed in a stationary cycle ergometers during 40 min, 3 times/week, for 8 weeks at 50–85% maximal heart rate (HRmax) in HIIT and 50% HRmax in MCT. Endothelial function was measured by flow-mediated dilation (FMD) [endothelium-depende...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Publication date: Available online 10 March 2019Source: NeuroscienceAuthor(s): Sabine Paeschke, Petra Baum, Klaus V. Toyka, Matthias Blüher, Severin Koj, Nora Klöting, Ingo Bechmann, Joachim Thiery, Joanna Kosacka, Marcin NowickiAbstractPeripheral diabetic neuropathy (PDN) is one of the common complications of diabetes mellitus. Previous studies showed an association between dietary iron load and inflammation in the development of PDN in a rat model of type 1 diabetes (T1D). Here we investigated the role of iron and neural inflammation in development of PDN in the animal model of obesity and type 2 diabetes (T2D)...
Source: Neuroscience - Category: Neuroscience Source Type: research
The objective of this manuscript is to compare pregabalin's efficacy and safety for painful diabetic peripheral neuropathy (pDPN) in subjects with type 1 (T1DM) or 2 diabetes mellitus (T2DM). METHODS: Pooled data from 10 randomized clinical trials (pregabalin-treated T1DM and T2DM subjects with pDPN) were analyzed for change from baseline (CFB) scores (pain and sleep disturbance) using mixed model repeated measures (MMRM) through Week 12 and last observation carried forward (LOCF). Adverse events (AEs) were recorded. RESULTS: Pregabalin-treated (T1DM 156 [8.7%]; T2DM 1632 [91.3%]) and placebo subjects (T1DM 92 [9.6...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
This study examined possible clinical factors associated with the symptoms of constipation in patients with DM. MethodsThis was a multicenter study. Participants were consecutive Japanese patients undergoing treatment for type 1 or type 2 DM. Constipation was evaluated using the gastrointestinal symptom rating scale. Diabetic neuropathy was evaluated by the presence or absence of peripheral neuropathy of the lower limbs. ResultsOf 419 participants, 258 were men and 161 women (ratio: 1.6:1), with a mean age of 63.6 ± 12.5 years. In multivariate analysis, symptoms of constipation were significantly associated with age...
Source: Journal of Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Gastroenterology Source Type: research
Conclusion: Presence of orthostatic hypotension in diabetics is associated with higher prevalence of macrovascular and microvascular complications of diabetes mellitus and also with higher 10-year mortality.
Source: Hypertension - Category: Cardiology Authors: Tags: Poster Abstract Presentations Source Type: research
This article is protected by copyright. All rights reserved
Source: Journal of Cellular Biochemistry - Category: Biochemistry Authors: Tags: Prospects Source Type: research
Type 2 diabetes (T2DM) is a major public health problem worldwide. It is estimated that 366 million people will be affected by T2DM till the year of 2030[1,2]. Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes. The lifetime incidence of DPN is approximately 45% for patients with type 2 diabetes mellitus and 54% to 59% for patients with type 1 diabetes mellitus [3,4]. In China, peripheral neuropathy is demonstrated to be popular among diabetics, pre-diabetics and even among normal population [5].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Conclusions:Detection of subtle nerve dysfunction will aid in the prevention of DPN complications and encourage patients for prompt metabolic control of their disease.Disclosure: Dr. Ahmed has nothing to disclose. Dr. Abuelwafaa has nothing to disclose. Dr. Omer has nothing to disclose. Dr. Abdullah has nothing to disclose. Dr. Ahmed has nothing to disclose. Dr. Musa has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: Neuromuscular and Clinial Neurophysiology (EMG): Peripheral Neuropathy II Source Type: research
More News: Antidoxidants | Brain | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Neurology | Organic | Peripheral Neuropathy | Selenium | Study